Acticor Biotech SAS Valuation
Is ALACT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Book vs. similares
Price-To-Book vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of ALACT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: ALACT (€4.9) cotiza por debajo de nuestra estimación de valor razonable (€96.23)
Muy por debajo del valor justo: ALACT cotiza por debajo de su valor razonable en más de un 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALACT?
Other financial metrics that can be useful for relative valuation.
| What is ALACT's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €44.66m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -2.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ALACT's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.8x | ||
ALGEN genOway Société anonyme | 2.2x | n/a | €37.3m |
ALNOV Novacyt | 0.3x | n/a | €36.3m |
ABNX ABIONYX Pharma | 7.4x | -43.4% | €35.4m |
ALVAL Valbiotis | 5.4x | 63.4% | €63.6m |
ALACT Acticor Biotech SAS | 121.4x | 81.5% | €44.7m |
Price-To-Book vs. similares: ALACT es caro según su Ratio Price-To-Book (174.9x) en comparación con la media de sus homólogos (2.9x).
Price to Earnings Ratio vs Industry
How does ALACT's PE Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Book vs. Industria: ALACT es caro en función de su Ratio Price-To-Book (174.9x) en comparación con la media del sector French Biotechs (2.4x).
Price to Book Ratio vs Fair Ratio
What is ALACT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 121.4x |
| Fair PB Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular ALACT's Price-To-Book Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.